ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
The facility will manufacture tablets, capsules, and injections for the oncology segment
Both organisations enter into a long- term collaboration to expand patient access in India
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Subscribe To Our Newsletter & Stay Updated
